All In Biotech

NDA 022088 · Pf Prism Cv

Torisel

Temsirolimus · Intravenous

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Mar 23, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

May 30, 2007

Approved uses

4

Original approval plus efficacy supplements

Registered trials

938

98 Phase 3, 68 recruiting

FAERS reports

4,506

3,854 serious, 969 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 26, 2025.

TORISEL is indicated for the treatment of advanced renal cell carcinoma. TORISEL ® is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma. ( 1 )

Mechanism: Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TORISEL · TEMSIROLIMUS 25MG/ML (25MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Temsirolimus" as an intervention, any sponsor and status, largest first.

All 938 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • disease progression479
  • death287
  • dyspnoea216
  • fatigue206
  • pneumonia190
  • diarrhoea189
  • nausea189
  • anaemia188
  • pyrexia179
  • vomiting176
  • thrombocytopenia164
  • dehydration162

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20064
2007132
2008422
2009352
2010523
2011426
2012538
2013399
2014279
2015328
2016247
2017153
2018132
2019119
2020106
202179
2022138
202360
202444
202516
20269

Recalls

2 FDA enforcement reports for this application.

  • Oct 10, 2014 · Class III · Terminated

    Crystallization: Impurities in a raw material used to manufacture the diluent can cause the formation of crystals in the diluent vials after cold storage. The TORISEL vials are not affected by this issue.

  • Nov 26, 2012 · Class III · Terminated

    Lack of Assurance of Sterility; potential that a low level of endotoxins may be present in the diluent vials.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 248 on PubMed

Sponsor: Pf Prism Cv

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.